Is Citius Pharmaceuticals Stock a Good Investment?
Citius Pharmaceuticals Investment Advice | CTXR |
- Examine Citius Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Citius Pharmaceuticals' leadership team and their track record. Good management can help Citius Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Citius Pharmaceuticals' business and its evolving consumer preferences.
- Compare Citius Pharmaceuticals' performance and market position to its competitors. Analyze how Citius Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Citius Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Citius Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Citius Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Citius Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Citius Pharmaceuticals Stock
Researching Citius Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.3. Some equities with similar Price to Book (P/B) outperform the market in the long run. Citius Pharmaceuticals recorded a loss per share of 0.24. The entity last dividend was issued on the 9th of June 2017. The firm had 1:15 split on the 9th of June 2017.
To determine if Citius Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Citius Pharmaceuticals' research are outlined below:
| Citius Pharmaceuticals generated a negative expected return over the last 90 days | |
| Citius Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (32.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Citius Pharmaceuticals currently holds about 48.04 M in cash with (29.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Citius Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Citius Pharmaceuticals Shares Gap Down Whats Next |
Citius Pharmaceuticals Quarterly Good Will |
|
Citius Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Citius Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Citius Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of January 2025 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Citius Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Citius Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-12 | 2024-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2024-05-14 | 2024-03-31 | -0.06 | -0.05 | 0.01 | 16 | ||
2023-08-14 | 2023-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2022-12-22 | 2022-09-30 | -0.04 | -0.05 | -0.01 | 25 | ||
2022-08-11 | 2022-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2020-08-14 | 2020-06-30 | -0.1 | -0.11 | -0.01 | 10 | ||
2022-05-12 | 2022-03-31 | -0.07 | -0.05 | 0.02 | 28 | ||
2021-12-15 | 2021-09-30 | -0.04 | -0.02 | 0.02 | 50 |
Know Citius Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Citius Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Citius Pharmaceuticals backward and forwards among themselves. Citius Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Citius Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wealth Advisory Solutions, Llc | 2024-09-30 | 201 K | Arkadios Wealth Advisors | 2024-09-30 | 200 K | Susquehanna International Group, Llp | 2024-09-30 | 165.1 K | Bank Of America Corp | 2024-06-30 | 159.4 K | Inspire Advisors, Llc | 2024-09-30 | 157.9 K | Point72 Asia (singapore) Pte. Ltd | 2024-09-30 | 100.5 K | Miller Investment Management, Lp | 2024-09-30 | 99.6 K | Xtx Topco Ltd | 2024-09-30 | 93.3 K | Kestra Advisory Services, Llc | 2024-09-30 | 92.5 K | Armistice Capital, Llc | 2024-09-30 | 7.3 M | Vanguard Group Inc | 2024-09-30 | 6.4 M |
Citius Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 87.15 M.Market Cap |
|
Citius Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.84) | (0.88) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.28) | (0.30) | |
| Return On Equity | (0.41) | (0.39) |
Determining Citius Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Citius Pharmaceuticals is a good buy. For example, gross profit margin measures Citius Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Citius Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Citius Pharmaceuticals' management efficiency
Citius Pharmaceuticals has return on total asset (ROA) of (0.2474) % which means that it has lost $0.2474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4149) %, meaning that it created substantial loss on money invested by shareholders. Citius Pharmaceuticals' management efficiency ratios could be used to measure how well Citius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/02/2024, Return On Tangible Assets is likely to drop to -0.88. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Citius Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 12/02/2024, Total Current Assets is likely to grow to about 41.5 M, while Non Currrent Assets Other are likely to drop slightly above 41.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.56 | 1.04 | |
| Tangible Asset Value | -41.3 K | -43.3 K | |
| Tangible Book Value Per Share | 0.14 | 0.15 | |
| Enterprise Value Over EBITDA | (60.63) | (63.66) | |
| Price Book Value Ratio | 24.77 | 26.01 | |
| Enterprise Value Multiple | (60.63) | (63.66) | |
| Price Fair Value | 24.77 | 26.01 | |
| Enterprise Value | 3.9 B | 4.1 B |
The management strategies employed by Citius Pharmaceuticals' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.663 |
Basic technical analysis of Citius Stock
As of the 2nd of December, Citius Pharmaceuticals shows the Standard Deviation of 8.48, mean deviation of 5.37, and Risk Adjusted Performance of (0.15). Citius Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Citius Pharmaceuticals market risk adjusted performance and treynor ratio to decide if Citius Pharmaceuticals is priced correctly, providing market reflects its regular price of 3.22 per share. Given that Citius Pharmaceuticals has information ratio of (0.23), we suggest you to validate Citius Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Citius Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Citius Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Citius Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Citius Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Citius Pharmaceuticals' Outstanding Corporate Bonds
Citius Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Citius Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Citius bonds can be classified according to their maturity, which is the date when Citius Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| C 5240588 25 JAN 26 Corp BondUS17327CAP86 | View | |
| C 3057 25 JAN 33 Corp BondUS17327CAQ69 | View | |
| C 2014 25 JAN 26 Corp BondUS17327CAN39 | View | |
| CITIGROUP INC Corp BondUS17327CAM55 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| US17328WP446 Corp BondUS17328WP446 | View |
Understand Citius Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Citius Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (1.08) | |||
| Mean Deviation | 5.37 | |||
| Coefficient Of Variation | (469.64) | |||
| Standard Deviation | 8.48 | |||
| Variance | 71.97 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (2.03) | |||
| Total Risk Alpha | (3.23) | |||
| Treynor Ratio | (1.09) | |||
| Maximum Drawdown | 49.26 | |||
| Value At Risk | (14.83) | |||
| Potential Upside | 10.14 | |||
| Skewness | (1.08) | |||
| Kurtosis | 6.0 |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | (1.08) | |||
| Mean Deviation | 5.37 | |||
| Coefficient Of Variation | (469.64) | |||
| Standard Deviation | 8.48 | |||
| Variance | 71.97 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (2.03) | |||
| Total Risk Alpha | (3.23) | |||
| Treynor Ratio | (1.09) | |||
| Maximum Drawdown | 49.26 | |||
| Value At Risk | (14.83) | |||
| Potential Upside | 10.14 | |||
| Skewness | (1.08) | |||
| Kurtosis | 6.0 |
Consider Citius Pharmaceuticals' intraday indicators
Citius Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Citius Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 28642.34 | |||
| Daily Balance Of Power | (0.29) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 3.15 | |||
| Day Typical Price | 3.17 | |||
| Price Action Indicator | 0.02 | |||
| Period Momentum Indicator | (0.10) |
Citius Pharmaceuticals Corporate Filings
F3 | 27th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 18th of November 2024 Other Reports | ViewVerify | |
F4 | 12th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Citius Stock media impact
Far too much social signal, news, headlines, and media speculation about Citius Pharmaceuticals that are available to investors today. That information is available publicly through Citius media outlets and privately through word of mouth or via Citius internal channels. However, regardless of the origin, that massive amount of Citius data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Citius Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Citius Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Citius Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Citius Pharmaceuticals alpha.
Citius Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Citius Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Citius Pharmaceuticals Corporate Management
| Myron MD | Executive Officer | Profile | |
| Dhananjay Wadekar | Senior Strategy | Profile | |
| Catherine MS | Executive Affairs | Profile | |
| Nikolas Burlew | Executive Assurance | Profile | |
| Ilanit Allen | Vice Communications | Profile |
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.